Biogen is a leading developer of drug therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, MA, for nearly 40 years, the Biogen team has worked to combat the effects of diseases such as MS, Alzheimer’s and spinal muscular atrophy. Biogen is in the process of rolling out its Aducanumab drug, which is designed to treat the symptoms of Alzheimer’s. Phase 1b results noted that the drug significantly slowed the decline in Alzheimer’s patients, giving hope to the over 25 million people around the world who suffer from the disease.
View Resource: Click Here to View the Content